In the News: 02/04

Celebrex Or Vioxx? Its A Toss Up Despite some heated claims and counter-claims, selective COX-2 inhibitors celecoxib (Celebrex) and rofecoxib (Vioxx) have been found to be equally effective. This was the finding following a study by Dr. Allan Gibofsky and his colleagues at Cornell Universitys Weill Medical College. The head-to-head, placebo-controlled test, reported in the November 2003 Arthritis & Rheumatism, involved 475 patients with knee osteoarthritis who were given celecoxib (200mg/day), rofecoxib (25mg/day), or a placebo.…
To continue reading this article or issue you must be a paid subscriber. Sign in

Subscribe to Arthritis Advisor

Get the next year of Arthritis Advisor for just $20. And access all of our online content - over 1,000 articles - free of charge.
Subscribe today and save 36%. It's like getting 4 months FREE!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access